Oncolytics Biotech Inc.

TSX:ONC Stock Report

Market Cap: CA$110.2m

Oncolytics Biotech Valuation

Is ONC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ONC (CA$1.34) is trading below our estimate of fair value (CA$57.61)

Significantly Below Fair Value: ONC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONC?

Key metric: As ONC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ONC. This is calculated by dividing ONC's market cap by their current book value.
What is ONC's PB Ratio?
PB Ratio11.4x
BookCA$9.06m
Market CapCA$110.22m

Price to Book Ratio vs Peers

How does ONC's PB Ratio compare to its peers?

The above table shows the PB ratio for ONC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.6x
MSCL Satellos Bioscience
4.6x-15.1%CA$100.2m
COV Covalon Technologies
4.1xn/aCA$89.0m
MDNA Medicenna Therapeutics
6.3x55.7%CA$135.2m
EPRX Eupraxia Pharmaceuticals
11.5xn/aCA$159.9m
ONC Oncolytics Biotech
11.4x37.5%CA$110.2m

Price-To-Book vs Peers: ONC is expensive based on its Price-To-Book Ratio (11.4x) compared to the peer average (6.6x).

Price to Book Ratio vs Industry

How does ONC's PB Ratio compare vs other companies in the CA Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
CSCI COSCIENS Biopharma
0.4xn/aUS$8.70m
MPH Medicure
0.5xn/aUS$6.37m
QPT Quest PharmaTech
0.2xn/aUS$3.53m
No more companies available in this PB range
ONC 11.4xIndustry Avg. 4.1xNo. of Companies3PB0246810+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ONC is expensive based on its Price-To-Book Ratio (11.4x) compared to the Canadian Biotechs industry average (4.1x).

Price to Book Ratio vs Fair Ratio

What is ONC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio11.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ONC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ONC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$1.34
CA$6.75
+403.7%
32.5%CA$9.00CA$3.50n/a4
Dec ’25CA$1.32
CA$6.75
+411.4%
32.5%CA$9.00CA$3.50n/a4
Nov ’25CA$1.66
CA$6.75
+306.6%
32.5%CA$9.00CA$3.50n/a4
Oct ’25CA$1.18
CA$6.75
+472.0%
32.5%CA$9.00CA$3.50n/a4
Sep ’25CA$1.28
CA$6.63
+417.6%
35.9%CA$9.00CA$3.00n/a4
Aug ’25CA$1.48
CA$6.63
+347.6%
35.9%CA$9.00CA$3.00n/a4
Jul ’25CA$1.35
CA$6.63
+390.7%
35.9%CA$9.00CA$3.00n/a4
Jun ’25CA$1.46
CA$6.63
+353.8%
35.9%CA$9.00CA$3.00n/a4
May ’25CA$1.54
CA$6.63
+330.2%
35.9%CA$9.00CA$3.00n/a4
Apr ’25CA$1.43
CA$7.83
+447.8%
16.8%CA$9.00CA$6.00n/a3
Mar ’25CA$1.51
CA$7.83
+418.8%
16.8%CA$9.00CA$6.00n/a3
Feb ’25CA$1.59
CA$7.83
+392.7%
16.8%CA$9.00CA$6.00n/a3
Jan ’25CA$1.79
CA$7.83
+337.6%
16.8%CA$9.00CA$6.00n/a3
Dec ’24CA$1.90
CA$7.83
+312.3%
16.8%CA$9.00CA$6.00CA$1.323
Nov ’24CA$2.23
CA$7.83
+251.3%
16.8%CA$9.00CA$6.00CA$1.663
Oct ’24CA$2.97
CA$7.83
+163.7%
16.8%CA$9.00CA$6.00CA$1.183
Sep ’24CA$3.23
CA$7.83
+142.5%
16.8%CA$9.00CA$6.00CA$1.283
Aug ’24CA$3.16
CA$7.83
+147.9%
16.8%CA$9.00CA$6.00CA$1.483
Jul ’24CA$3.49
CA$7.83
+124.5%
16.8%CA$9.00CA$6.00CA$1.353
Jun ’24CA$2.24
CA$7.83
+249.7%
16.8%CA$9.00CA$6.00CA$1.463
May ’24CA$2.15
CA$7.83
+264.3%
16.8%CA$9.00CA$6.00CA$1.543
Apr ’24CA$1.65
CA$7.83
+374.7%
16.8%CA$9.00CA$6.00CA$1.433
Mar ’24CA$2.09
CA$7.25
+246.9%
17.2%CA$8.50CA$6.00CA$1.512
Feb ’24CA$2.49
CA$7.25
+191.2%
17.2%CA$8.50CA$6.00CA$1.592
Jan ’24CA$2.22
CA$7.25
+226.6%
17.2%CA$8.50CA$6.00CA$1.792
Dec ’23CA$2.82
CA$7.25
+157.1%
17.2%CA$8.50CA$6.00CA$1.902

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 07:01
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncolytics Biotech Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
John NewmanCanaccord Genuity
Douglas LoeCantor Fitzgerald Canada Corporation